Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001211479 | SCV001383020 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2O; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine with glutamic acid at codon 109 of the POMGNT1 protein (p.Lys109Glu). The lysine residue is highly conserved and there is a small physicochemical difference between lysine and glutamic acid. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with POMGNT1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C55"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV003132275 | SCV003811736 | uncertain significance | not provided | 2019-06-28 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001833854 | SCV002090230 | uncertain significance | Muscle eye brain disease | 2021-05-27 | no assertion criteria provided | clinical testing |